**Question:** A women delivered a baby of 2.2 kg weight. Her LMP is not known. To know the maturity of baby, following are used –

A. Fetal lung maturity testing (e.g., alpha-fetoprotein, surfactant profile)
B. Non-stress test (NST)
C. Oligohydramnios or polyhydramnios
D. Maternal age or gestational age

**Core Concept:** Determining fetal maturity is crucial in assessing the risk of respiratory distress syndrome (RDS) in premature infants. LMP (last menstrual period) helps in calculating gestational age, which is essential to evaluate fetal maturity.

**Why the Correct Answer is Right:** When LMP is unknown, gestational age cannot be accurately calculated. Therefore, we use other methods to assess fetal maturity.

A. Fetal lung maturity testing, such as alpha-fetoprotein (AFP) and surfactant profile, evaluates the lung maturity indirectly by assessing the production and composition of lung proteins. AFP is produced by the liver and crosses the placenta, while surfactant proteins B and C are present in the amniotic fluid.

B. Non-stress test (NST) assesses fetal heart rate variability and decelerations. A reactive NST indicates a healthy fetus, while an inadequate NST raises concern about fetal well-being and may indicate premature labor.

C. Oligohydramnios (low amniotic fluid volume) and polyhydramnios (high amniotic fluid volume) can be signs of fetal maturity or immaturity. However, they do not solely determine fetal maturity.

D. Maternal age or gestational age is unreliable for assessing fetal maturity when LMP is unknown. Instead, we rely on indirect markers and clinical examination, as maternal age alone cannot accurately predict fetal lung maturity and well-being.

**Why Each Wrong Option is Incorrect:**

D. Maternal age is an unreliable indicator of fetal maturity when LMP is unknown. Fetal lung maturity is determined by indirect markers like lung enzymes, decelerations, and amniotic fluid volume.

Core Concept: Assessing fetal maturity is essential to prevent complications like respiratory distress syndrome (RDS) in premature infants. Gestational age estimation is crucial in this process, but it becomes unreliable when LMP is unknown. Therefore, we use other methods, including fetal lung enzyme assays, fetal heart rate variability, and amniotic fluid volume assessment.

**Clinical Pearls:**

1. Gestational age estimation relies on LMP, but when unknown, alternative methods are crucial to evaluate fetal maturity.
2. Fetal lung maturity assessment involves indirect markers like lung enzymes, fetal heart rate variability, and amniotic fluid volume.
3. Clinical pearls emphasize the importance of accurate gestational age estimation and the necessity of using alternative methods when LMP is unknown.